Immunotherapy in the treatment of advanced or recurrent endometrial cancer.
Clin Adv Hematol Oncol
; 22(3): 129-139, 2024 Apr.
Article
em En
| MEDLINE
| ID: mdl-38588272
ABSTRACT
The standard treatment of patients with advanced or recurrent endometrial cancer has not significantly changed over the past few decades, reflecting a major unmet clinical need. Fortunately, the arrival of immune checkpoint inhibition is rapidly changing this dismal scenario. This review discusses the most recent results from clinical trials evaluating the use of immune checkpoint inhibitors, either as monotherapy or in combination therapy, in both the post-platinum and frontline settings. Additionally, a section is devoted to the future clinical development of immune checkpoint inhibitors in advanced or recurrent endometrial cancer.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias do Endométrio
/
Inibidores de Checkpoint Imunológico
Limite:
Female
/
Humans
Idioma:
En
Revista:
Clin Adv Hematol Oncol
Assunto da revista:
HEMATOLOGIA
/
NEOPLASIAS
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Espanha